AN2 Therapeutics, Inc.
ANTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $77 | $0 |
| Gross Profit | $0 | $0 | -$77 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $40,488 | $54,871 | $29,511 | $16,906 |
| G&A Expenses | $14,066 | $14,764 | $12,751 | $4,668 |
| SG&A Expenses | $14,066 | $14,764 | $12,751 | $4,668 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $54,554 | $69,635 | $42,185 | $21,574 |
| Operating Income | -$54,554 | -$69,635 | -$42,262 | -$21,574 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,233 | $4,903 | $1,306 | $31 |
| Pre-Tax Income | -$51,321 | -$64,732 | -$40,956 | -$21,543 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51,321 | -$64,732 | -$40,956 | -$21,543 |
| % Margin | – | – | – | – |
| EPS | -1.72 | -2.74 | -2.79 | -1.5 |
| % Growth | 37.2% | 1.8% | -86% | – |
| EPS Diluted | -1.72 | -2.74 | -2.79 | -1.5 |
| Weighted Avg Shares Out | 29,828 | 23,600 | 15,340 | 18,740 |
| Weighted Avg Shares Out Dil | 29,828 | 23,600 | 15,340 | 18,740 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,467 | $0 | $1,351 | $69 |
| Interest Expense | $0 | $0 | $514 | $0 |
| Depreciation & Amortization | $54,554 | $69,635 | $77 | $0 |
| EBITDA | $3,233 | $4,903 | -$40,879 | -$21,574 |
| % Margin | – | – | – | – |